FLXN Flexion Therapeutics Inc

Price (delayed)

$9.16

Market cap

$457.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.2

Enterprise value

$589.42M

Highlights
The EPS is up by 42% year-on-year and by 13% since the previous quarter
The net income is up by 27% year-on-year and by 7% since the previous quarter
FLXN's equity has dropped by 133% since the previous quarter but it is up by 26% year-on-year
Flexion Therapeutics's quick ratio has decreased by 27% YoY and by 14% QoQ
Flexion Therapeutics's gross margin has decreased by 15% YoY and by 4% QoQ

Key stats

What are the main financial stats of FLXN
Market
Shares outstanding
49.94M
Market cap
$457.47M
Enterprise value
$589.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
5.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.55
Earnings
Revenue
$90.01M
EBIT
-$84.47M
EBITDA
-$80.78M
Free cash flow
-$68.44M
Per share
EPS
-$2.2
Free cash flow per share
-$1.37
Book value per share
-$0.78
Revenue per share
$1.81
TBVPS
$4.62
Balance sheet
Total assets
$230.38M
Total liabilities
$269.25M
Debt
$230.65M
Equity
-$38.87M
Working capital
$146.64M
Liquidity
Debt to equity
-5.93
Current ratio
3.53
Quick ratio
3.18
Net debt/EBITDA
-1.63
Margins
EBITDA margin
-89.7%
Gross margin
74.4%
Net margin
-117.2%
Operating margin
-92.9%
Efficiency
Return on assets
-41.5%
Return on equity
N/A
Return on invested capital
-27.8%
Return on capital employed
-49%
Return on sales
-93.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FLXN stock price

How has the Flexion Therapeutics stock price performed over time
Intraday
-1.61%
1 week
-1.51%
1 month
8.4%
1 year
-30.29%
YTD
-20.62%
QTD
2.35%

Financial performance

How have Flexion Therapeutics's revenue and profit performed over time
Revenue
$90.01M
Gross profit
$66.96M
Operating income
-$83.58M
Net income
-$105.46M
Gross margin
74.4%
Net margin
-117.2%
Flexion Therapeutics's operating margin has increased by 41% YoY and by 15% from the previous quarter
FLXN's operating income is up by 36% YoY and by 10% from the previous quarter
The net margin has grown by 33% YoY and by 12% from the previous quarter
The net income is up by 27% year-on-year and by 7% since the previous quarter

Growth

What is Flexion Therapeutics's growth rate over time

Valuation

What is Flexion Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
5.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.55
The EPS is up by 42% year-on-year and by 13% since the previous quarter
FLXN's equity has dropped by 133% since the previous quarter but it is up by 26% year-on-year
The P/S is 16% below the last 4 quarters average of 6.0
FLXN's revenue is up by 9% YoY and by 5% from the previous quarter

Efficiency

How efficient is Flexion Therapeutics business performance
The return on sales is up by 39% year-on-year and by 14% since the previous quarter
The ROA has grown by 36% YoY and by 10% from the previous quarter
Flexion Therapeutics's ROIC has increased by 33% YoY and by 11% from the previous quarter

Dividends

What is FLXN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FLXN.

Financial health

How did Flexion Therapeutics financials performed over time
FLXN's total assets is 14% smaller than its total liabilities
FLXN's current ratio is down by 31% YoY and by 14% QoQ
Flexion Therapeutics's quick ratio has decreased by 27% YoY and by 14% QoQ
FLXN's equity has dropped by 133% since the previous quarter but it is up by 26% year-on-year
FLXN's debt to equity has soared by 57% QoQ but it is down by 38% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.